ABSTRACT. Some cases of primary hyperphenylalaninemia are not caused by the lack of phenylalanine hydroxylase, but by the lack of its cofactor tetrahydrobiopterin. These patients are not clinically responsive to a phenylalanine-restricted diet, but need specific substitution therapy. Thus, it became necessary to examine all newborns screened as positive with the Guthrie test for tetrahydrobiopterin deficiency. Methods based on urinary pterin or on specific enzyme activity measurements are limited in their availability, and the simplest method, based on the lowering of serum phenylalanine after loading with cofactor, was discouraged by the finding that some dihydropteridine reductase-deficient patients were unresponsive. The preliminary observation that this limitation could be overcome by increasing the dose of the administered cofactor prompted us to reevaluate the potential of the tetrahydrobiopterin loading test in hyperphenylalaninemia. Fifteen patients, eight with ultimate diagnosis of phenylketonuria, three with 6-pyruvoyl tetrahydropterin synthase-, and four with dihydropterine reductase-deficiency, have been examined by administering synthetic tetrahydrobiopterin both orally, at doses of 7.5 and 20 mg/kg, and i.v., at a dose of 2 mg/kg. All the tetrahydrobiopterin-deficient patients, unlike those with phenylketonuria, responded to the oral dose of 20 mg/kg cofactor by lowering their serum phenylalanine concentration markedly below baseline to an extent easily detectable by Guthrie cards. This method allows for a simple screening method when enzyme or pterin studies are not available. (Pediatr Res 30: [435][436][437][438] 1991) 
PKU to describe some cases clinically unresponsive to a Pherestricted diet and later shown to be due to BH4 deficiency ( 1-4).
By analyzing all the essential components of the complex hydroxylation system of aromatic amino acids, it became apparent that a defect in the BH4 recycling enzyme DHPR (EC 1.66.99.7) and two defects in BH4 synthetic pathway enzymes, guanosine triphosphate cyclohydrolase I (EC 3.5.4.16) and 6-PPH4S, may lead to cofactor deficiency resulting in HPA and in impaired production of dopamine and serotonin (5) (6) (7) . Dietary treatment in these patients does not prevent brain damage. These patients need early cofactor and/or neurotransmitter substitutive therapy. Thus, it became necessary to reexamine all the newborns having HPA for BH4 deficiency (8-1 1).
A frequency of 1-3% among patients with HPA has been estimated for BH4 deficiency in worldwide surveys (12) . Further study might prove the frequency of these disorders to be higher not only in the Mediterranean area, as previously suggested (1 3), but also in non-Caucasian populations. The prevalence of BH4 deficiency among all HPA is over 15% in Piedmont, Italy, appears to be even higher in infants of Turkish origin (14) , and is up to 50% among Guthrie-positive patients in Taiwan (1 5) .
Several procedures are now available for defining which component of the Phe hydroxylating system is affected (10) . Ideal methods are those based on the direct measurement of specific enzyme activities. However, with the exception of DHPR assay, which is easily performed on dried blood spots (16), they are not widely used because of their complexity and because of the limited expression of PH, guanosine triphosphate cyclohydrolase I and 6-PPH4S activity in body tissues. Indirect methods, relying on HPLC to define urinary pterin excretion, are widely used. They enable, with some minor uncertainties (17) , the detection of BH, deficiency as well as the discrimination of the different types of deficiency. The limitation is that only a few laboratories are able to carry them out.
Historically, the first method tried (1 8), and predicted as the most convenient for a selected screening among HPA (19) , exploited the lowering of serum Phe in BH4-deficient patients after the administration of exogenous BH4. An i.v. loading with 2 mg/kg BH, was originally proposed by Danks et al. (19) . With the increased purity and availability of synthetic cofactor, an oral loading test was introduced by Curtius et al. (20) and standardized at the dose of 7.5 mg/kg in its current form by Niederwieser et al. (2 l) , possibly allowing a very simple method to discriminate between hyperphenylalaninemic patients with PH and BH4 deficiency. However, it soon became obvious that some DHPRdeficient patients could be misdiagnosed, inasmuch as their serum Phe is not lowered after the load, introducing an unacceptable limitation of this test if solely used (10) .
The recent observations that BH4 nonresponsiveness in DHPR deficiency correlated with the presence of a mutant enzyme (22) and that it could be overcome by increasing the dose of the were measured every 2 h after the load. All these different BH4 loading tests were performed at basal serum Phe concentrations Patient selection. The study population consisted of 15 patients ranging from 33 1 to 239 1 ~m o l / L . Cofactor absorption was (seven males and eight females) positively identified through the proven in all cases by the measurement of total biopterin in neonatal mass screening for PKU or subsequently at an older urine collected 12-0 h before and 4-8 h after oral loading. age as having HPA at the ages of 12 d to 5 y. Differential diagnosis among HPA patients was performed by following the RESULTS criteria and the procedures previously reported (10) . Diagnosis of PKU was accepted after exclusion of transient or secondary BH4 orally, 7.5 mglkg. None of the PKU patients responded forms of HPA and, after the selected screening of BH4 deficiency to this oral loading test (Table 2) . Serum Phe and Tyr concentrathrough the analysis of urinary pterins (lo), the measurement of tions showed limited and unequivocal fluctuations, possibly due specific enzyme activities (10, 16, 22, 24) , in addition to the BH4 to resumption of a free diet just after loading. All three 6-PPH4S-oral loading test (10) . The PKU phenotype was settled by the deficient patients and only one DHPR-deficient patient (the evaluation of the dietary Phe tolerance and the oral Phe loading CRM-patient) lowered their basal serum Phe concentration test (25) .
( Tables 3 and 4 ). All the BH4-deficient patients (including the Eight patients had an ultimate diagnosis of PH deficiency with three DHPR-CRM+ patients) increased their basal serum Tyr the phenotype of classical PKU (cases 1-81> three had 6-PPH4S concentration after the load. When positive, the response apdeficiency (cases I-III), and four had DHPR deficiency (cases a-peared more rapid and lowered the Phe more in 6-PPH4S defid) ( Table 1 ). All DHPR-deficient patients showed no enzyme ciency when with DHPR deficiency, activity by assay of dried blood spots (16) , and an antibody study B H~ orally, 20 mg/kg. When loaded with 20 mg/kg BH4, the (z2) demonstrated in one case (a) the absence of any enzyme PKU patients again showed no significant fluctuation of serum protein (DHPR-CRM-) and in three cases (b, c, and d, the Phe concentrations (Table 2) , whereas serum Phe concentration presence a mutant protein lacking (DHPR-fell in all the DHPR-CRM+ patients who previously had not CRM+).
responded to the oral load with 7.5 mg/kg ( Table 4 ). The time BH4 loading tests (6RS)-~-erthro-tetrahydrobiopterin dihy-course of serum Tyr concentration in the DHPR-deficient padrochloride (BH4.2HCl; Dr. Schirks Laboratory, Wettswill A.A., tients was similar to that observed with the lesser dose of BH4 Switzerland) was administered orally to all patients at the dose of 7.5 mg/kg before the institution of dietary restriction or but with a more pronounced increase. Again, maximum effect cofactor therapy. BH4 was administered after 6 h fasting and 30 observed at 8 h. S u~~s~~g~~, serum T~r did rnin before the meal to ensure good absorption, after dissolving rise in some PKU patients, with a maximal response 4 h after the tablets in 20 mL of water in dim light. Blood samples were the load 2). taken immediately before and 4 and 8 h after loading. Serum BH4 mglkg. Both in PKU patients and in DHPRPhe and Tyr were measured chromagraphically with the Kro-CRM+ patients, the response was similar to that obtained with makon 500 automatic analyzer (Kontron, Everett, MA). The the oral loading at the dose of 20 mg/kg, but the cofactor effects three DHpR-CRM+ patients who did not respond to the load appeared more pronounced by i.v. loading in the first hours after with 7.5 mg/kg BH4 and five PKU patients were reloaded orally the load (Tables 2 and 4 ). Even so, the kinetics and the extent of with 20 mg/kg BH4, following the above procedures. At this the response appeared markedly different between patients b and time, fasting Phe levels were raised because of fortuitous discon-c (Table 4 ). * Diagnosis of PH deficiency (PH-), 6-PPH4S deficiency (6-PPH4S-) and DHPR deficiency (DHPR-) was obtained by the analysis of urinary pterin excretion, the measurement of 6-PPH4S and DHPR activity, and the evaluation of a BH, oral loading test. t mmol/mol creatinine.
$ %B = 100 x biopterin/(biopterin + neopterin). § d J / g Hb.
11 nmol cytochrome c reduced/min/5-mm diameter filter paper disc.
n On cultured skin fibroblasts. ** Reference values from Dr. N. Blau, Head, Screening Laboratory, University Children's Hospital, Zurich, Switzerland. Epidemiologic evidence suggests that every newborn with HPA should be evaluated for BH4 deficiency (8-1 1) . The nature of BH4 deficiency justifies its inclusion in screening programs as part of the PKU mass screening program, needing additional screening in only positively identified newborns. The BH4 loading test was recognized as most convenient for this purpose (26), depending on its reliability for the detection of DHPR deficiency (10) . The data obtained from the present study confirm and extend our previous preliminary report (23) patients who do not respond to a load dose of 7.5 mg/kg BH4 in fact do respond (by lowering serum Phe) to 20 mg/kg. This finding does not clarify the paradox that in DHPR deficiency BH4 should be functioning stoichiometrically and not catalytically (27) , because BH4 should barely lower serum Phe in these cases if there were a stoichiometric conversation of Phe to Tyr (28) . Serum amino acid kinetics of the load test response are quite different in 6-PPH4S deficiency and in DHPR deficiency, allowing to some extent the discrimination of BH4 synthesis from BH4 regeneration defects. None of the five PKU patients tested at the higher cofactor level in this study showed a positive response, but possibly larger numbers of PKU patients have to be analyzed to exclude that some PKU variant might be BH4-responsive. The main point regarding the diagnostic potential of the BH4 loading test among HPA patients is the present observation that higher cofactor doses did produce a positive response in our "nonresponding" DHPR-deficient patients, allowing discrimination of all present cases of BH4 deficiency from PKU. Yet ultimate diagnoses of subtypes will require more complex tests (10) . Since the publication of our preliminary findings (23), two DHPR-deficient patients have been described who did not respond to the higher level of BH4 (17, 29, Kaufman S, personal communication). The lack of response in these patients might be explained by a specific mutation causing unresponsiveness, the coexistence of DHPR deficiency and PKU, or defective BH4 absorption. Unfortunately, those patients died before any of these hypotheses could be tested, including still higher doses of BH4, which might have elicited a Phe-lowering response. This is a critical point, considering the clinical application of just the BH4 loading test for the screening for BH4 deficiency. Cofactor unresponsiveness of some very rare DHPR-deficient patients must still be regarded as a remotely possible cause of missing a diagnosis with the high BH4 level oral loading test. Consequently, present knowledge suggests that for full reliability this simple clinic-based test should be coupled with a blood spot test (16) for DHPR activity assay.
An additional reason for performing the BH4 loading test in HPA is that it is a functional test, and results may give some indication on the patient's treatment, outcome, and overall prognosis. Thus, in DHPR deficiency, several different BH, response categories can now be characterized: 7.5 mg/kg responsive, 7.5 mg/kg unresponsive but 20 mg/kg responsive, and, possibly, 20 mg/kg unresponsive. So far we have little data on 438 PONZONE ET AL. I the correlation of these categories with response to therapy and prognosis. However, an earlier study (30) suggested that cases responding to lower levels of BH4 may be less severe. These studies also indicated that nonresponsiveness to 7.5 mg/kg of BH4 correlated with the presence of inactive enzymes (22) . It is also conceivable that a cofactor-responsive form of PKU may exist and that a BH4 loading test would detect such cases.
The outcome of a BH4 loading test is usually judged by the presence or absence of a precipitous fall in previously elevated serum Phe concentrations, and slight falls are usually regarded as negative. This leaves open to question whether it is the percentage of the absolute fall of serum Phe level that is more relevant. If larger series of cases are studied with standardized BH, loading tests, it may be possible to discriminate the different types of BH4 deficiency and indeed the different DHPR response categories. Also, the kinetics of serum Tyr response may appear to be quite different in patients with cofactor synthesis or regeneration defects, and the evaluation of the changes in the Phe/ Tyr ratio at 0.4, and 8 h may help to discriminate less obvious differences.
Among the present cases studied, the oral test gave a more clear-cut response than the i.v. test in one case of DHPR deficiency. The reason for this unexpected discrepancy is unknown, but it may be that genotypic definition of underlying mutant alleles will allow us to distinguish the type of response.
